ATE307608T1 - Kombination von doctaxel und rhumab her2 zür krebsbehandlung - Google Patents

Kombination von doctaxel und rhumab her2 zür krebsbehandlung

Info

Publication number
ATE307608T1
ATE307608T1 AT00923156T AT00923156T ATE307608T1 AT E307608 T1 ATE307608 T1 AT E307608T1 AT 00923156 T AT00923156 T AT 00923156T AT 00923156 T AT00923156 T AT 00923156T AT E307608 T1 ATE307608 T1 AT E307608T1
Authority
AT
Austria
Prior art keywords
rhumab her2
doctaxel
combination
cancer treatment
docetaxel
Prior art date
Application number
AT00923156T
Other languages
English (en)
Inventor
Charles Le Vogel
Robert E Bellet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22435924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE307608(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE307608T1 publication Critical patent/ATE307608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Drying Of Gases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00923156T 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zür krebsbehandlung ATE307608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12856499P 1999-04-09 1999-04-09
PCT/US2000/009247 WO2000061185A1 (en) 1999-04-09 2000-04-07 Docetaxel in combination with rhumab her2 for the treatment of cancers

Publications (1)

Publication Number Publication Date
ATE307608T1 true ATE307608T1 (de) 2005-11-15

Family

ID=22435924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923156T ATE307608T1 (de) 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zür krebsbehandlung

Country Status (22)

Country Link
US (1) US6333348B1 (de)
EP (1) EP1169059B1 (de)
JP (2) JP2003512298A (de)
KR (1) KR100695383B1 (de)
CN (1) CN1191859C (de)
AT (1) ATE307608T1 (de)
AU (1) AU777661B2 (de)
BR (1) BR0009647A (de)
CA (1) CA2368369C (de)
CZ (1) CZ296373B6 (de)
DE (1) DE60023476T2 (de)
DK (1) DK1169059T3 (de)
EA (1) EA006097B1 (de)
ES (1) ES2248070T3 (de)
HK (2) HK1046093B (de)
HU (1) HU226672B1 (de)
MX (1) MXPA01010138A (de)
NO (1) NO332619B1 (de)
NZ (1) NZ515337A (de)
TR (1) TR200102845T2 (de)
WO (1) WO2000061185A1 (de)
ZA (1) ZA200107771B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
CA2333147C (en) * 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2282120T3 (es) * 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU2002232413A1 (en) * 2000-11-21 2002-06-03 Cell Pathways, Inc. Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
MX368013B (es) 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
EP1390078A4 (de) * 2001-04-26 2005-10-26 Analogic Corp Ct-scanner für die darstellung eines vorab festgelegten teils eines patienten
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
KR20120068769A (ko) * 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
CA2624086A1 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
FR2904782B1 (fr) * 2006-08-11 2008-10-31 Delta Proteomics Soc Par Actio Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2133433A1 (de) * 2008-06-09 2009-12-16 Centre Georges François Leclerc Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010061269A2 (en) * 2008-11-02 2010-06-03 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
RS58784B1 (sr) 2010-05-06 2019-06-28 Milosavljevic Goran Farmaceutske kompozicije niske toksičnosti koje sadrže diterpenska jedinjenja sa antineoplastičnim dejstvom
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
CA2847218C (en) * 2011-09-01 2018-02-27 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids
CN102321175B (zh) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 针对乳腺癌Her2/new的纳米抗体或多肽
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN109966499A (zh) * 2019-04-25 2019-07-05 苏州大学 协同增效的抗乳腺癌转移药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers

Also Published As

Publication number Publication date
DK1169059T3 (da) 2006-02-27
DE60023476T2 (de) 2006-07-06
NO20014842L (no) 2001-10-04
ES2248070T3 (es) 2006-03-16
EP1169059A1 (de) 2002-01-09
HUP0201459A2 (en) 2002-09-28
HU226672B1 (en) 2009-06-29
CN1350464A (zh) 2002-05-22
NO20014842D0 (no) 2001-10-04
CN1191859C (zh) 2005-03-09
MXPA01010138A (es) 2003-07-14
NZ515337A (en) 2003-10-31
DE60023476D1 (de) 2005-12-01
HK1046093B (zh) 2005-10-28
ZA200107771B (en) 2002-09-20
JP2012136535A (ja) 2012-07-19
EP1169059B1 (de) 2005-10-26
WO2000061185A1 (en) 2000-10-19
CA2368369A1 (en) 2000-10-19
HK1043313A1 (zh) 2002-09-13
AU777661B2 (en) 2004-10-28
EA006097B1 (ru) 2005-08-25
HK1046093A1 (en) 2002-12-27
US6333348B1 (en) 2001-12-25
HUP0201459A3 (en) 2003-04-28
KR20020007358A (ko) 2002-01-26
CZ296373B6 (cs) 2006-03-15
TR200102845T2 (tr) 2002-01-21
NO332619B1 (no) 2012-11-19
JP2003512298A (ja) 2003-04-02
CZ20013614A3 (cs) 2002-07-17
AU4332700A (en) 2000-11-14
BR0009647A (pt) 2002-01-08
KR100695383B1 (ko) 2007-03-15
EA200101064A1 (ru) 2002-04-25
CA2368369C (en) 2014-03-25

Similar Documents

Publication Publication Date Title
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
WO2002017852A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
MXPA04001912A (es) Aminobenzofenonas novedosas.
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
DK1150981T3 (da) Terapeutisk necleosidforbindelse
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169059

Country of ref document: EP